Guru Sonpavde: ESMO24 bladder cancer practice-changing highlight

Guru Sonpavde, Genitourinary Oncology and Phase I Clinical Trials Director of Chair of Bladder Cancer Research at AdventHealth Central Florida, shared a post on LinkedIn:

“ESMO24 bladder cancer practice-changing highlight:

AMBASSADOR Phase III clinical trial led by Andrea Apolo at the Alliance for Clinical Trials in Oncology, with participation from SWOG Cancer Research Network and Eastern Cooperative Oncology Group.

Among patients with high-risk muscle-invasive urothelial carcinoma after radical surgery, disease-free survival (DFS) was significantly longer with adjuvant pembrolizumab for 1 year versus observation—median DFS doubled to 29.6 vs. 14.2 months (hazard ratio 0.73; 2-sided P = 0.003).

Honored to coauthor from AdventHealth Central Florida and Dana-Farber Cancer Institute in an oral presentation and concurrent publication in the New England Journal of Medicine.

Pleased to comment in Video Journal of Oncology.”

Source: Guru Sonpavde/LinkedIn